| Trial Identifier: | D8664C09827 |
| Sponsor: | AstraZeneca |
| NCTID:: | NCT03971110 |
| Start Date: | January 2021 |
| Primary Completion Date: | November 2022 |
| Study Completion Date: | November 2022 |
| Condition: | Prostate Cancer |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| English Version | |
| Chinese Translation |
| Country | Location |
|---|---|
| CN | Beijing, CN, 100034 |
| CN | Changsha, CN, 430033 |
| CN | Changsha, CN, 410013 |
| CN | Chengdu, CN, 610041 |
| CN | guangzhou, CN, 510080 |
| CN | Guangzhou, CN, 510630 |
| CN | Hangzhou, CN, 310020 |
| CN | Hangzhou, CN, 310014 |
| CN | Hefei, CN, 230022 |
| CN | Shanghai, CN, 200032 |
| CN | shenyang, CN, 110001 |
| CN | Shijiazhuang, CN, 050001 |
| CN | Urumqi, CN, 830054 |
| CN | Xi'an, CN, 710061 |
| CN | Zhengzhou, CN |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company